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Purpose: In a large cohort of molecularly characterized inherited retinal disease (IRD) families, we investi-
gated proportions with disease attributable to causative variants in each gene.
Design: Retrospective study of electronic patient records.
Participants: Patients and relatives managed in the Genetics Service of Moorfields Eye Hospital in whom a
molecular diagnosis had been identified.
Methods: Genetic screening used a combination of single-gene testing, gene panel testing, whole exome
sequencing, and more recently, whole genome sequencing. For this study, genes listed in the Retinal Information
Network online resource (https://sph.uth.edu/retnet/) were included. Transcript length was extracted for each
gene (Ensembl, release 94).
Main Outcome Measures: We calculated proportions of families with IRD attributable to variants in each
gene in the entire cohort, a cohort younger than 18 years, and a current cohort (at least 1 patient encounter
between January 1, 2017, and August 2, 2019). Additionally, we explored correlation between numbers of families
and gene transcript length.
Results: We identified 3195 families with a molecular diagnosis (variants in 135 genes), including 4236
affected individuals. The pediatric cohort comprised 452 individuals from 411 families (66 genes). The current
cohort comprised 2614 families (131 genes; 3130 affected individuals). The 20 most frequently implicated genes
overall (with prevalence rates per families) were as follows: ABCA4 (20.8%), USH2A (9.1%), RPGR (5.1%), PRPH2
(4.6%), BEST1 (3.9%), RS1 (3.5%), RP1 (3.3%), RHO (3.3%), CHM (2.7%), CRB1 (2.1%), PRPF31 (1.8%), MY07A
(1.7%), OPA1 (1.6%), CNGB3 (1.4%), RPE65 (1.2%), EYS (1.2%), GUCY2D (1.2%), PROM1 (1.2%), CNGA3
(1.1%), and RDH12 (1.1%). These accounted for 71.8% of all molecularly diagnosed families. Spearman co-
efficients for correlation between numbers of families and transcript length were 0.20 (P ¼ 0.025) overall and 0.27
(P ¼ 0.017), e0.17 (P ¼ 0.46), and 0.71 (P ¼ 0.047) for genes in which variants exclusively cause recessive,
dominant, or X-linked disease, respectively.
Conclusions: Our findings help to quantify the burden of IRD attributable to each gene. More than 70% of
families showed pathogenic variants in 1 of 20 genes. Transcript length (relevant to gene delivery strategies) correlated
significantly with numbers of affected families (but not for dominant disease). Ophthalmology 2020;127:1384-
1394 ª 2020 by the American Academy of Ophthalmology. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Supplemental material available at www.aaojournal.org.Monogenic retinal diseases are a major cause of blindness in
the pediatric and working-age population in many
countries.1e3 Pathogenic variants in more than 250 genes
can give rise to inherited retinal disease (IRD), with multiple
modes of inheritance.4 For most of these diseases, no
medical or surgical treatments exist, but a large number of1384 ª 2020 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativec
org/licenses/by/4.0/). Published by Elsevier Inc.therapeutic trials are underway.5 Currently a commercially
available licensed gene-replacement treatment is available
for a particular genetic cause: IRD resulting from biallelic
variants in RPE65.6 Because more therapies are likely to
become available in the future, with many likely to be
specific to a particular genetic cause, it is of increasingommons.
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Pontikos et al  Genetic Diagnosis in a Large UK IRD Cohortrelevance to understand the burden of disease attributable to
variants in particular genes.
The Genetics Service of Moorfields Eye Hospital over-
sees the care of the largest number of IRD patients of any
one site in the United Kingdom. A significant proportion of
these families have a molecular diagnosis, more recently
with the advent of parallel nucleotide sequencing and the
availability of whole genome sequencing.7 When positive
genetic diagnoses are made, regarded by the specialist
physicians to be in keeping with the patients’ clinical
phenotypes and modes of inheritance, these are recorded
with the pedigrees in the electronic record. In this study,
we interrogated the database to quantify the number of
families with pathogenic variants in different genes to
build a picture of the most prevalent causes of IRD,
within the limitations of such a retrospective analysis. We
performed a similar analysis exclusively in patients
younger than 18 years to explore the burden of disease in
the pediatric cohort. We also investigated relationships
between gene transcript length (of relevance when
considering development of gene replacement therapies)
and number of families affected. Herein, we highlight in
particular the 20 most frequently implicated genes, which
accounted for more than 70% of the cohort.
Methods
Genetic Database Search
Specialist clinics at Moorfields Eye Hospital receive secondary and
tertiary referrals for patients with suspected IRD from throughout
the United Kingdom. Probands, and in many cases family mem-
bers, are examined by experienced retinal specialists. After a
family is considered solved by the physician (A.R.W., M.M.,
A.T.M., P.Y.-W.-M., O.M.), the causative gene is recorded within
a genetics module within the hospital electronic patient record
(OpenEyes Electronic Medical Record, Apperta Foundation, Sun-
derland, Tyne And Wear, UK). Each pedigree has a unique iden-
tifier. In this study, we interrogated the back-end database
retrospectively to identify all families with IRD in whom a positive
molecular diagnosis had been made. The search date was August 2,
2019, and identified all families in whom a patient encounter had
occurred since 2003.
Genetic Testing Pathway at Moorfields Eye
Hospital
Patients are referred to the retinal genetics service when their pri-
mary care physician, optometrist or ophthalmologist suspects an
IRD. A detailed clinical history is obtained from the patient (and, in
the case of children, their parents or guardians), which includes the
presence of symptoms, age at onset of symptoms, and order of
onset of symptoms, including night vision problems, central vision
disturbances, photophobia or hemeralopia, as well as a full medical
history and family history (including construction of a pedigree).
Patients undergo ophthalmic examination, including visual acuity
and intraocular pressure measurement, slit-lamp biomicroscopy,
and retinal imaging, comprising spectral-domain OCT and short-
wavelength fundus autofluorescence (not always possible in chil-
dren). Some patients also undergo electroretinography. If patients
are suspected by the IRD physician of having an IRD, genetic
testing is discussed. In the past, screening was performed mostcommonly by Sanger sequencing of single genes or small panels.
The decision to go ahead with genetic testing in the past was based
on a number of factors including the patient’s eagerness to be
tested (to help inform prognosis and likelihood of transmission to
future generations), the likelihood of positive results, and the
possibility of a particular genetic cause that may enable eligibility
to treatment trials (early examples were RPE65 and CHM).
In the last decade, next generation sequencing of large gene
panels has become more accessible, and testing in our service has
been offered more widely and relatively less prone to the above
biases. Over the last 5 to 7 years, including the period covering the
current cohort of the present study, our service has sought to offer
the opportunity for investigating the molecular diagnosis in all
patients suspected by the specialist physician of having an IRD.
The costs are not borne directly by the patients themselves, but
rather are covered by bodies including the National Health Service
(NHS) or its research arm, the National Institute of Health
Research. Patients with retinitis pigmentosa, other monogenic
chorioretinal degenerations, macular dystrophies, cone and
coneerod dystrophies, stationary conditions (including stationary
night blindness and achromatopsia), and suspected syndromic
retinal dystrophies all undergo genetic testing. Some patients
(including those late in life, who may have no children) may
decline genetic testing, but most choose to undergo testing. In
some cases, including conditions with very mild changes evident
on retinal imaging and minimal symptoms, or adult vitelliform
maculopathies, where the chances of a positive genetic diagnosis
are lower, genetic testing has not been considered uniformly.
Figure S1 (available at www.aaojournal.org) broadly illustrates the
methods and sequence for genetic testing.
During the past 5 years, the following strategy was adopted for
genetic testing. For patients with a retinal dystrophy affecting
generalized retinal function (with abnormal full-field scotopic or
photopic electroretinography results), a gene panel test was offered
covering more than 150 genes known to be implicated in retinal
dystrophies (usually performed by the Manchester Centre for
Genomic Medicine). In the presence of known autosomal dominant
or X-linked inheritance, a restricted panel was requested covering
the relevant genes; for X-linked retinal degeneration, this included
a request for specific sequencing of the ORF15 exon of RPGR
because pathogenic variants in this region can be easily missed. For
macular dystrophies, restricted panels were requested, frequently
using the Stargardt/Macular Dystrophy Panel of the Molecular
Vision Laboratory (Hillsboro, OR). Single-gene testing was per-
formed in very few patients in recent years, usually only when a
recognizable phenotype implicated a single gene (for example,
testing for RS1 in a male with retinoschisis, a pedigree suggestive
of X-linked inheritance, and a negative electroretinogram wave-
form). Where results of gene panels were negative, but a mono-
genic disorder was still strongly suspected, further sequencing was
initiated if available (as part of either a clinical or research test),
including whole genome sequencing.
Whole genome sequencing was available as part of a number of
national research projects from 2013 onward. Initially, this was via
the National Institute of Health Research Bioresource project
(described in a previous publication)8 and later as part of the
100 000 Genomes project.7 For the latter study, patients were
recruited to a pilot study from 2014, with the main study
recruiting from 2015 until September 2018. Initial recruitment to
the 100 000 Genomes project was for patients who previously
showed negative results in initial gene panel screening and for
whom DNA samples from additional family members were
available. Later, criteria were relaxed, and patients with
suspected monogenic disease and no prior testing were eligible,
even if samples from family members were not available. The1385
Ophthalmology Volume 127, Number 10, October 2020largest number of retinal disease patients was recruited to this study
via the retinal genetics service of Moorfields Eye Hospital. When
possible, results for patients from our institution are reviewed by
a multidisciplinary panel including molecular biologists, clinical
geneticists, and the retinal specialist managing the family, and
consensus is reached, taking into account prior reports of
pathogenicity of the variant,9 prevalence in publicly available
genome databases, the clinical phenotype, and mode of
inheritance, before the molecular diagnosis is established.
Approximately 600 probands in the cohort of the present study
achieved a molecular diagnosis by whole genome sequencing.
Finally, before access to whole genome sequencing, whole
exome sequencing was performed for a number of families (some,
but not all, of whom showed negative results previously with
single-gene or limited gene panel screening). This testing was
performed largely at the Institute of Ophthalmology, University
College London, and achieved a molecular diagnosis in approxi-
mately 160 families of the cohort reported in this article.
Inclusion of Genes and Transcript Lengths
For the purposes of the present study, only genes listed on the
Retinal Information Network online resource (https://sph.uth.edu/
retnet/; accessed October 10, 2019) were included. Transcript
lengths for each gene were extracted from online resources
(Ensembl, release 94; longest transcript chosen in case of multiple
transcripts). We calculated the correlation between numbers of
families affected by variants in each gene and the gene’s transcript
size. Because the data were not normally distributed, Spearman
correlation coefficients were used.
Consent and Ethical Approval
Patients and relatives gave written informed consent for genetic
testing. The study received relevant local research ethics committee
approval (Moorfields Eye Hospital and the Northwest London




Our study identified 4236 individuals from 3195 families with a
molecular diagnosis for their disease. Pathogenic variants were
found in 135 distinct genes. The full dataset is given in Table S1
(available at www.aaojournal.org). The 20 most frequently
implicated genes (by number of affected families) were as
follows: ABCA4 (20.8% of families), USH2A (9.1% of families),
RPGR (5.1% of families), PRPH2 (4.6% of families), BEST1
(3.9% of families), RS1 (3.5% of families), RP1 (3.3% of
families), RHO (3.3% of families), CHM (2.7% of families),
CRB1 (2.1% of families), PRPF31 (1.8% of families), MY07A
(1.7% of families), OPA1 (1.6% of families), CNGB3 (1.4% of
families), RPE65 (1.2% of families), EYS (1.2% of families),
GUCY2D (1.2% of families), PROM1 (1.2% of families),
CNGA3 (1.1% of families), RDH12 (1.1% of families). These
accounted for 71.8% of all molecularly characterized families.
Table 1 summarizes key features of these genes, and Figure 1
schematically demonstrates expression by cellular subtype.
Figure 2 illustrates numbers affected by the 30 most frequently
implicated genes (by number of affected families and numbers of
affected individuals, upper and lower panels, respectively). When
genes are ranked by numbers of individuals affected, rather than
families, autosomal dominant genes, as expected, move upward
in rank (e.g., RHO, TIMP3, PRPF8).1386Among the families, 85.3% showed causative variants in
autosomal genes (most frequently ABCA4, USH2A, PRPH2, and
BEST1), 13.7% in X-linked genes (most commonly RPGR, RS1,
and CHM), and 1.0% in mitochondrial genes (including those
implicated in Leber hereditary optic neuropathy and maternally
inherited diabetes and deafness). Of the autosomal genes, most
were genes in which variants acted exclusively recessively (52.6%
of all families); 8.2% of families showed variants in genes in which
disease-causing variants are solely dominant, and 24.5% of fam-
ilies showed variants in genes that can contain dominant or
recessively acting pathogenic variants.
For patients with autosomal dominant retinitis pigmentosa (RP),
the most frequently associated genes were RHO, RP1, and
PRPF31; for X-linked and autosomal recessive forms of RP, the
most frequently associated genes were RPGR and USH2A,
respectively. For macular dystrophies, the most common gene by
far was ABCA4 (autosomal recessive), whereas PRPH2 and BEST1
were implicated frequently in autosomal dominantly inherited
macular dystrophies.
For all genes (excluding mitochondrial), the Spearman co-
efficient of correlation between number of families and tran-
script size was 0.20 (P ¼ 0.025). Figure 3 separately plots
numbers of families against transcript size for autosomal
genes in which variants act solely recessively (Fig 3A),
autosomal genes in which variants are solely dominant (Fig
3B), and X-linked genes (Fig 3C). A significant positive
correlation was observed in each case, with the exception of
autosomal dominant genes.Ethnicity and Phenotypic Subtypes
Data on ethnicity were not recorded uniformly for all of the pa-
tients in the genetics service. However, these data were available
almost completely for all of the families recruited from our service
for whole genome sequencing via the 100 000 Genomes project.
This distribution of ethnicity is representative of our cohort. Of
1287 IRD probands recruited to the main project, 62.2% were
white, 17.9% were Asian (largely South Asian), 7.0% were black
(African, Caribbean, and other black background), and 1.8% were
of mixed race or ethnicity. These reflect a combination of the de-
mographics of London and the wider United Kingdom (given that
many patients seen in the genetics service are referred from outside
London, and sometimes from outside England). The full ethnic
distribution is presented in Figure S2 (available at
www.aaojournal.org).
We also were not able to extract phenotypic subgroups readily
in an automated way from the electronic data record because of the
variability in data entry and diagnostic labelling. However, this
information was available for the above 1287 probands. Of this
group, the largest diagnostic category was rodecone dystrophy
(49%), followed by macular dystrophy (35%), inherited optic
neuropathy (4.9%), Leber congenital amaurosis or early-onset se-
vere retinal dystrophy (3%), rod dysfunction syndrome (3%), cone
dysfunction syndrome (2%), and familial exudative vitreoretinop-
athy (2%). Entries were limited to these categories; patients with
cone dystrophies were entered within the macular dystrophy or
cone dysfunction categories. The proportions were similar within
each of the major ethnic categories (white, Asian, black), and
pairwise comparisons did not reveal significant differences, except
for a smaller proportion of Asian patients (29.4%) being diagnosed
with macular dystrophy than the corresponding proportions of
white (36.6%) or black (43.3%) patients and more Asian patients
being diagnosed with familial exudative vitreoretinopathy (4.3%)
than black patients (0%). However, the differences were no longer
significant after correction for multiple testing.







Affected (%) Methods of Inheritance Range of Phenotypes in the Literature
ABCA4 1p22.1 666 (20.8) 789 (18.6) Recessive Stargardt macular dystrophy. coneerod
dystrophy
USH2A 1q41 292 (9.1) 342 (8.1) Recessive RP, type 2 Usher syndrome
RPGR Xp11.4 164 (5.1) 263 (6.2) X-linked RP, cone or coneerod dystrophy
PRPH2 6p21.1 148 (4.6) 220 (5.2) Dominant and recessive Pattern dystrophy, RP
BEST1 11q12.3 125 (3.9) 168 (4.0) Dominant and recessive Best disease, autosomal recessive
bestrophinopathy
RS1 Xp22.13 111 (3.5) 134 (3.2) X-linked X-linked retinoschisis
RP1 8q12.1 106 (3.3) 170 (4.0) Dominant and recessive RP
RHO 3q22.1 105 (3.3) 177 (4.2) Dominant and recessive RP, stationary night blindness
CHM Xq21.2 86 (2.7) 112 (2.6) X-linked Choroideremia
CRB1 1q31.3 68 (2.1) 86 (2.0) Recessive LCA, RP, macular dystrophy
PRPF31 19q13.42 57 (1.8) 94 (2.2) Dominant RP
MYO7A 11q13.5 53 (1.7) 58 (1.4) Recessive Type 1 Usher syndrome
OPA1 3q29 50 (1.6) 84 (2.0) Dominant Optic atrophy, optic atrophy with
sensorineural hearing loss
CNGB3 8q21.3 44 (1.4) 55 (1.3) Recessive Achromatopsia, cone dystrophy
RPE65 1p31.2 39 (1.2) 51 (1.2) Recessive and dominant LCA, RP
EYS 6q12 38 (1.2) 43 (1.0) Recessive RP
GUCY2D 17p13.1 37 (1.2) 54 (1.3) Recessive and dominant LCA, RP, cone or coneerod dystrophy
PROM1 4p15.32 37 (1.2) 53 (1.2) Recessive and dominant Macular dystrophy, coneerod
dystrophy, RP
CNGA3 2q11.2 36 (1.1) 50 (1.2) Recessive Achromatopsia, cone dystrophy
RDH12 14q24.1 35 (1.1) 44 (1.0) Recessive and dominant LCA, RP
LCA ¼ Leber congenital amaurosis; RP ¼ retinitis pigmentosa.
Methods of inheritance and range of possible phenotypes are given.
Pontikos et al  Genetic Diagnosis in a Large UK IRD CohortPediatric Cohort
To explore burden of disease in a pediatric population, an addi-
tional analysis was performed separately for patients younger than
18 years. Our search yielded 452 individuals from 411 molecularly
diagnosed families with variants in 66 genes. This dataset is given
in Table S2 (available at www.aaojournal.org). The 69 genes
implicated in the overall dataset that were not present in those
younger than 18 years in our cohort are listed separately in
Table S3 (available at www.aaojournal.org). Figure 4 illustrates
the 30 most frequently encountered genes by number of affected
families or affected individuals (for comparison with Fig 2). In
this cohort, the top 20 genes accounted for 73% of the cohort
(by number of affected families).Figure 1. Schematic of the retina showing site of expression of proteins
encoded by the 20 most frequently implicated genes in the cohort. RPE ¼
retinal pigment epithelium.In the pediatric cohort, 78.8% of families showed causative
variants in autosomal genes (most frequently ABCA4 and BEST1),
20.7% in X-linked genes (most commonly RS1 and RPGR), and
0.5% in mitochondrial genes (associated with Leber hereditary
optic neuropathy). Of the autosomal genes, most were genes in
which variants acted exclusively recessively (47.7% of all fam-
ilies); 8.8% of families showed variants in genes in which disease-
causing variants are solely dominant; 22.4% showed variants in
genes that can contain dominant or recessively acting pathogenic
variants. In comparison with the overall cohort, the proportion of
families with causative variants in X-linked genes was significantly
greater in the pediatric cohort (P < 0.001).
The X-linked genes in both cohorts included RPGR (associated
with RP or coneerod dystrophy), RS1 (associated with X-linked
retinoschisis), CHM (choroideremia), CACNA1F (incomplete
congenital stationary night blindness), RP2 (associated with RP),
NYX (complete congenital stationary night blindness), and NDP
(associated with Norrie disease or X-linked familial exudative
vitreoretinopathy). Of these, some affected female patients were
seen in the overall cohort with disease associated with RPGR,
CHM, and RP2, consistent with the possibility of female patients
demonstrating symptoms. These tend to be milder and usually
appear later in life than in male patients. Thus, in the pediatric
cohort, very few affected female patients were seen for the X-
linked genes (only 2 female patients were recorded as being
affected by variants in RPGR).
Notably also, PRPH2 and USH2A were not among the most
frequently implicated genes, in contrast to the overall cohort,
consistent with variants in these genes more frequently leading to
visual impairment later in life, relative to some of the other
commonly associated genes. However, some genes associated with
congenital stable, or very early-onset progressive, visual impairment1387
Figure 2. Bar graphs showing the 30 most frequently involved genes in the full cohort. A, Genes ranked by numbers of affected families. B, Genes ranked by
numbers of affected individuals.
Ophthalmology Volume 127, Number 10, October 2020were among the top 10 genes in the pediatric cohort, but not in the
overall cohort, as follows: CACNA1F, associated with incomplete
congenital stationary night blindness; CNGA3 and CNGB3, associ-
ated with achromatopsia; and RPE65 and CRB1, associated with
Leber congenital amaurosis or early-onset severe retinal dystrophy.
Current Cohort
To reduce the bias inherent in the inclusion of all molecularly
characterized families, some of whom will not have accessed the
clinical services for many years, but whose data appears because of
a historic and specific interest in their disorder or ease of genetic
testing for a specific gene, we conducted a third data search. This
was limited to families in which patients had undergone an
encounter with our service within the last 2 to 3 years (specifically
between January 1, 2017, and the search date, August 2, 2019).
This may include both clinical examination or a virtual clinic
consisting of correspondence with patients informing them of their
genetic results if these have only recently come to light.
This current cohort yielded 3130 individuals from 2614 distinct,
molecularly characterized families. Causative variants were in 131
genes. The full dataset is given in Table S4 (available at
www.aaojournal.org). The 20 most frequently implicated genes
accounted for 71.2% of the total number of families. Figure 5
illustrates the 30 most common genes by number of families
affected and by numbers of individuals, in the same format as
Figures 2 and 4. The order of genes was very similar to that in
the overall cohort. The proportions of families with causative
variants in X-linked genes (13.5%), in autosomal genes in which1388pathogenic variants act exclusively dominantly (8.3%), in auto-
somal genes in which variants act exclusively recessively (53.7%),
in autosomal genes in which pathogenic variants can be dominant
or recessive (23.5%), and in mitochondrial genes (0.9%) were not
significantly different from the corresponding proportions in the
overall cohort.Discussion
In this study, we investigated the burden of IRD attributable
to different genes in a large United Kingdom cohort of 3197
molecularly diagnosed families (more than 4000 affected
individuals). This is the largest published molecularly
solved IRD cohort to date, as far as the authors are aware.
Our families showed variants in 135 genes that are associ-
ated with IRD on the Retinal Information Network online
resource. We found that the 20 most frequently involved
genes accounted for more than 70% of the cohort. Of these
20 genes, 1 gene (RPE65) is the subject of licensed
commercially available gene therapy, and a further 7 genes
(ABCA4, CHM, CNGA3, CNGB3, MY07A, RPGR, and RS1)
are subjects of experimental gene-replacement trials.5
The most frequently encountered gene was ABCA4
(causing Stargardt macular dystrophy or coneerod dystro-
phy). The most frequent gene accounting for autosomal
recessive RP was USH2A. For autosomal dominant RP, the
Figure 3. Graphs showing the numbers of affected families plotted against transcript length. A, Autosomal genes in which pathogenic variants act
exclusively recessively (Spearman correlation coefficient, 0.27; P ¼ 0.017). B, Autosomal genes in which pathogenic variants act exclusively dominantly
(Spearman correlation coefficient, e0.17; P ¼ 0.459). C, X-linked genes (Spearman correlation coefficient, 0.71; P ¼ 0.047).
Pontikos et al  Genetic Diagnosis in a Large UK IRD Cohortmost commonly encountered genes were RHO, RP1, and
PRPF31. A significant proportion (nearly 40%) of X-linked
retinopathy was the result of variants in RPGR. Although, as
expected, the vast majority of affected individuals with
pathogenic variants in X-linked genes were male, some
affected female patients were recorded in the RPGR, CHM,
and RP2 gene groups, consistent with the known possibility
of female patients being affected; no affected female pa-
tients were found to be associated with the other X-linked
genes in the overall cohort (and no affected CHM or RP2
female patients were found in the pediatric cohort).
We additionally analyzed genes implicated in our pedi-
atric cohort and a more current subsection of the full cohort
in an attempt to mitigate partially the effect of historical bias
in the overall cohort. Although the current cohort was very
similar to the overall cohort, some important differences
were noted in the pediatric cohort. The proportion of fam-
ilies affected by variants in X-linked genes was significantly
higher in the pediatric cohort. This may reflect the earlier
onset and severity of some of the X-linked diseases, and also
the likelihood of earlier diagnosis in individuals in whom
parents and clinicians are alerted by a positive family history
(which is often absent in autosomal recessive conditions,
these forming the largest proportion of both cohorts). A
number of genes noted in the overall cohort were absent in
the pediatric cohort, which may reflect rarity of these vari-
ants (and hence their absence in a cohort of smaller size) or
that many genotypes lead to later-onset visual impairment.PRPH2 and USH2A were among the 5 most frequently
implicated genes in the overall cohort, but not the pediatric
cohort, consistent with older ages of diagnosis (or signifi-
cant visual impairment) in many cases. Conversely, a
number of genes with congenital or early-onset visual
impairment appeared more frequently in the pediatric cohort
(detailed in “Results”).
Findings in Other Cohorts
A number of prior studies have examined IRD
cohorts.4,8,10e26 Table 2 presents the most frequently
involved genes in many of these published studies over the
last 3 to 4 years. Obvious similarities exist in terms of
genes affected across diverse geographic regions. However,
interesting differences exist, too. Variants in FAM161A
account for a substantial proportion of disease in a large
Israeli cohort.11 Variants in EYS were a more frequent
cause of disease than were USH2A variants in Korean
patients12; this also has been reported in a large cohort of
Japanese RP patients.26 In a large Chinese RP cohort,
CYP4V2 was the second most implicated gene after
USH2A.27 Differences between populations can reflect
founder effects and are important in guiding genetic testing
and future interpretation of results of whole genome
sequencing. In addition, a relative paucity of studies of IRD
cohorts in other large regions, such as Africa, is apparent
and worthy of addressing in future investigations.1389
Figure 4. Bar graphs showing the 30 most frequently involved genes in the cohort younger than 18 years. A, Genes ranked by numbers of affected families.
B, Genes ranked by numbers of affected individuals.
Ophthalmology Volume 127, Number 10, October 2020Rates of consanguinity also differ between population
groups. When consanguinity or endogamy is more common,
autosomal recessive diseases associated with homozygous
variants will be more likely. Recently published findings
from the United Arab Emirates10 showed that the most
frequently implicated genes in a pediatric cohort were
those in which pathogenic variants are inherited
recessively, with many associated with homozygous
variants. In contrast, in our pediatric cohort, after ABCA4,
the next 4 most frequently inherited genes were associated
with X-linked or predominantly autosomal dominant
disease (although recessive disease did feature in a
number of the top 20 genes). Eliciting a history of
consanguinity can be helpful not just in selecting genes
for screening, but also in interpreting results of whole
genome sequencing, where preliminary focus concentrates
on regions of homozygosity. Other methods of inheritance
of course are possible, even in consanguineous cohorts.
For example, in the pediatric study from the United Arab
Emirates, RS1 (X-linked) and BEST1 (usually associated
with autosomal dominant disease) also featured in a
number of families.10
Genetic testing strategies and their accessibility also
differ among countries: those in which targeted restricted
gene panels are used selectively in patients with recog-
nizable phenotypes could lead to a greater reported prev-
alence of those genes (for example, possibly contributing
to the higher prevalence of KCNV2 retinopathy, which has
a pathognomonic electroretinography phenotype,28 in the
United Arab Emirates study).10 The availability of whole1390genome sequencing to a proportion of our cohort, as part
of a national research project, and access to particular
gene panels with testing paid for by the National Health
Service or its research arm may not be applicable to
other countries with different accessibility to clinical and
research tests and different arrangements for
reimbursement.
Correlations with Transcript Length
The length of the transcript is of relevance in the context of
gene replacement therapy; a limit exists to the size of cDNA
that can be delivered by different virus vectors. Adenoas-
sociated viruses have been a vector of choice for ocular gene
therapy trials, targeting retinal cells with relatively low
immunogenicity, but their capacity is limited.5 We explored
transcript lengths and relationships with numbers of families
affected. We found a weak, but statistically significant,
correlation in the overall cohort. For autosomal genes in
which pathogenic variants act recessively, the correlation
remained significant, whereas no apparent correlation was
found for dominant genes.
Longer transcripts may be expected, by virtue of their
length, to contain more sites in which a variant potentially
can bring about premature termination or loss of function,
which is the usual method of action in recessive disease.
Thus, a greater prevalence of pathogenic variants in longer
genes might be anticipated. For many dominant diseases,
however, loss of function variants in many cases do not
cause disease. Pathogenicity frequently is consequent on a
Figure 5. Bar graphs showing the 30 most frequently involved genes in the current cohort (in which a patient encounter had occurred within the preceding
2.5 years). A, Genes ranked by numbers of affected families. B, Genes ranked by numbers of affected individuals.
Pontikos et al  Genetic Diagnosis in a Large UK IRD Cohortgain of function or specific effects of mutations (for some
genes, only a few dominantly acting variants have been
identified), and so prevalence of disease may not be ex-
pected to correlate in the same way with transcript length. In
contrast, X-linked disease often is a result of loss of the
single functioning allele in male patients (and again longer
genes may have more sites at which mutation can lead to
premature termination or loss of function); this may explain
the significant correlation between number of affected
families and transcript size observed for X-linked genes
(although the number of genes here is relatively small).
Study Limitations
Our findings should be taken in the context of a number of
important limitations inherent in such a retrospective study.
The study relies on prior data entry, which may be incom-
plete or inconsistent or in some cases contain errors,
although efforts are made to correct these when they come
to light. It is likely that a number of genes are over-
represented, including those discovered earlier, those more
amenable to sequencing by earlier methods, or those in
which historic or current interest exists particularly in light
of potential gene-specific therapies. This effect will lessen
over time, as more patients have undergone whole genome
sequencing, permitting unbiased analysis of data. Detection
of structural variants and variants in noncoding regions still
can be challenging, as can detection of pathogenic variants
in the repetitive ORF15 exon of RPGR. The latter can beeasily missed in whole genome sequencing, and so the
burden of disease resulting from RPGR may be under-
estimated. In addition, some of the earlier results predate
current guidelines9 and the availability of large databases of
common variants, and so variants previously classified as
pathogenic may no longer be regarded as such.
We sought to mitigate partly the effect of historical biases
by performing a time-limited analysis of more current pa-
tient data, which represented a large proportion of the
overall cohort. During the period pertaining to the current
cohort, clinical or research genetic testing was offered
routinely to all patients who were reviewed in clinic and
were suspected by the specialist physician of having an IRD,
with no direct cost borne by the patient.
A further source of potential ascertainment bias relates to
the types of patients managed in our service. Although
Moorfields Eye Hospital cares for both children and adults,
some of the more severe syndromic conditions tend to be
managed in other specialist centers, with multidisciplinary
medical input. Thus, these disorders are likely to be un-
derrepresented in our cohort.
Given the retrospective nature of the study, we were
unable to ascertain a number of other potentially useful data.
The total number of patients enrolled for genetic testing was
not available, thus precluding calculation of a molecularly
solved rate for the entire cohort. Whole genome sequencing,
when available, was offered initially to patients who had
shown negative results with prior gene panels, but was
offered later to all patients, thus making this a mixed group.1391
Table 2. Selected Previous Studies in Inherited Retinal Disease Cohorts
Study Author(s) by Year Study Cohort or Country
No. of Molecularly
Diagnosed (No. of Genes) Most Frequently Implicated Genes
Current study United Kingdom 4241 individuals from 3197
families (135 genes)
By family: ABCA4, USH2A, RPGR, PRPH2, BEST1; by
individual: ABCA4, USH2A, RPGR, PRPH2, RHO
2019
Khan10 United Arab Emirates (children) 71 individuals (26 genes) ABCA4, KCNV2, CRB1, CNGA3
Sharon et al11 Israel 1369 families (129 genes) ABCA4, USH2A, FAM161A, CNGA3, EYS
Holtan et al12 Norway 207 patients (56 genes) ABCA4, USH2A, BEST1, RHO, RS1
Avela et al13 Finland (children) 41 families (17 genes) RS1, GUCY2D, RPGR
Kim et al14 Korea 38 individuals (24 genes) ABCA4, EYS, PDE6B, USH2A, PDE6A, GUCY2D
Tayebi et al15 Iran 36 families (19 genes) ABCA4, RPE65, CERKL, RPGRIP1
2018
Motta et al16 Brazil 400 individuals (66 genes) ABCA4, CEP290, USH2A, CRB1, RPGR
Wang et al17 China 132 families (47 genes) USH2A, RPGR, CYP4V2, ABCA4, CRB1, RHO
2017
Stone et al18 United States 760 families (104 genes) ABCA4, USH2A, RPGR, RHO, PRPH2
Carss et al8 United Kingdom 404 individuals (94 genes) ABCA4, USH2A, EYS, RP1, CACNA1F, RPGR
Dockery et al19,* Ireland (adults) 357 families (59 genes) ABCA4, USH2A, BBS1, RHO, RP1
Ellingford et al20 UK, genomic laboratory 271 individuals (62 genes) USH2A, CRB1, ABCA4, CERKL, CEP290
Haer-Wigman et al21 Netherlands 136 individuals (56 genes) USH2A, EYS, ABCA4, RPGR, GUCY2D, PDE6B
Riera et al22 Spain 42 individuals (29 genes) ABCA4, USH2A, PDE6A, CRB1, EYS, GUCY2D, PDE6B
2016
Tiwari et al23 Switzerland 58 individuals (18 genes) ABCA4, C2orf71, RP1, CEP290, FLVCR1, CRB1
Bernardis et al24 Italy 52 individuals (16 genes) ABCA4, USH2A, RPGR, CNGB1, BEST1
Some authors report results from gene panel or whole exome or whole genome testing, leading to likely underrepresentation of disorders diagnosed with
single-gene testing. Studies restricted to specific phenotypes (e.g., retinitis pigmentosa) are not shown. Some smaller cohorts are included to allow wider
geographical representation. The right-hand column gives the most frequently implicated genes. (In most cases, these are the top 5, but where multiple genes
contributed the same proportion, additional genes may be included.) For some 2019 studies, year published relates to year of online publication (print
publication in some cases was in 2020).
*Some data relating to this study were taken from the publication Farrar et al.4
Ophthalmology Volume 127, Number 10, October 2020In a prior study partly from our service,8 63% of patients
with no prior testing achieved a molecular diagnosis from
whole exome or whole genome sequencing, compared
with 54% of those who previously had shown negative
results on prior gene panels.
Also, the date of first symptoms or first clinical diag-
nosis was not available. Because of variability in data
entry, we could not extract readily the proportions attrib-
utable to particular variants of each gene, race or ethnicity
data by genotype, or the specific frequency of phenotypic
subgroups for the entire cohort, but these are useful sub-
jects for further exploration. Our findings thus give a sense
of relative burdens of disease attributable to different
genes in a large multiethnic United Kingdom-based cohort
but may not apply precisely to other populations with
different ethnic compositions (as discussed in relation to
Table 2) or with different availabilities or strategies for
genetic testing.
With parallel developments in genomic testing and
novel therapies, we envision that it will become a
standard of care to seek the molecular diagnosis in most
IRD patients. Quantification of disease burden attribut-
able to particular genes, and particular genetic variants,
in diverse populations will be important in both guiding
individual patient management and planning within
healthcare systems to address this important cause of
blindness.1392References
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Road, London EC1V 2PD, United Kingdom. E-mail: o.mahroo@ucl.ac.uk.Pictures & PerspectivesEmbedded Retinal Eyelash with Orbital Inflammation
A teenaged boy presented with a 2-week history of a red left eye and extraocular movement restriction with a history of contact lens
wear but denied a history of trauma. His visual acuity was 20/50, and a tender red nodule on the inferotemporal sclera (Fig A) with anterior
vitritis were found. Magnetic resonance imaging revealed enhancement of the lateral and inferior recti and adjacent fat (Fig B). An
intraocular foreign body (IOFB) embedded in the inferotemporal retina (Fig C) was found on fundoscopy and was later removed following
pars plana vitrectomy, resolving the intraocular and orbital inflammation. Final visual acuity was 20/25. Gross examination confirmed the
IOFB to be an eyelash (Fig D). (Magnified version of Fig A-D is available online at http://www.aaojournal.org).
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